Metropolitan Life Insurance Company (MetLife)’s Myriad Genetics MYGN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,619	Closed	-$98.5K	–	1344
2024 Q1	$98.5K	Sell	4,619 -317	-6%	-$6.82K	﹤0.01%	1059
2023 Q4	$94.5K	Hold	4,936	–	–	﹤0.01%	1119
2023 Q3	$79.2K	Buy	4,936 +415	+9%	+$7.9K	﹤0.01%	1142
2023 Q2	$105K	Hold	4,521	–	–	0.01%	998
2023 Q1	$105K	Sell	4,521 -489	-10%	-$9.93K	0.01%	972
2022 Q4	$72.7K	Hold	5,010	–	–	﹤0.01%	1246
2022 Q3	$95.6K	Hold	5,010	–	–	﹤0.01%	1041
2022 Q2	$91K	Hold	5,010	–	–	﹤0.01%	1106
2022 Q1	$126K	Sell	5,010 -15,255	-75%	-$390K	﹤0.01%	1058
2021 Q4	$559K	Hold	20,265	–	–	0.01%	1351
2021 Q3	$654K	Buy	20,265 +128	+0.6%	+$4.25K	0.01%	1272
2021 Q2	$616K	Buy	20,137 +936	+5%	+$27K	0.01%	1379
2021 Q1	$585K	Sell	19,201 -2,936	-13%	-$83.3K	0.01%	1326
2020 Q4	$438K	Hold	22,137	–	–	0.01%	1444
2020 Q3	$289K	Hold	22,137	–	–	﹤0.01%	1563
2020 Q2	$251K	Hold	22,137	–	–	﹤0.01%	1655
2020 Q1	$317K	Hold	22,137	–	–	0.01%	1331
2019 Q4	$603K	Sell	22,137 -446	-2%	-$12.3K	0.01%	1210
2019 Q3	$647K	Hold	22,583	–	–	0.01%	1128
2019 Q2	$627K	Buy	22,583 +291	+1%	+$8.22K	0.01%	1163
2019 Q1	$740K	Sell	22,292 -447	-2%	-$13.6K	0.01%	1053
2018 Q4	$661K	Buy	22,739 +1,791	+9%	+$64.4K	0.01%	1041
2018 Q3	$964K	Hold	20,948	–	–	0.02%	957
2018 Q2	$783K	Hold	20,948	–	–	0.01%	1049
2018 Q1	$619K	Buy	20,948 +502	+2%	+$17K	0.01%	1139
2017 Q4	$702K	Sell	20,446 -22,254	-52%	-$751K	0.01%	1068
2017 Q3	$1.54M	Sell	42,700 -1,532	-3%	-$43.7K	0.01%	1033
2017 Q2	$1.14M	Sell	44,232 -3,675	-8%	-$78K	0.01%	1173
2017 Q1	$920K	Sell	47,907 -1,524	-3%	-$27K	0.01%	1275
2016 Q4	$824K	Hold	49,431	–	–	0.01%	1405
2016 Q3	$1.02M	Hold	49,431	–	–	0.01%	1270
2016 Q2	$1.51M	Hold	49,431	–	–	0.01%	1041
2016 Q1	$1.85M	Buy	49,431 +1,341	+3%	+$50.5K	0.01%	920
2015 Q4	$2.08M	Sell	48,090 -744	-2%	-$31.4K	0.02%	883
2015 Q3	$1.83M	Buy	48,834 +363	+0.7%	+$12.9K	0.01%	939
2015 Q2	$1.65M	Buy	+48,471	New	+$1.65M	0.01%	1039
2015 Q1	–	Sell	-4,903	Closed	-$167K	–	2359
2014 Q4	$167K	Buy	4,903 +123	+3%	+$4.36K	﹤0.01%	2523
2014 Q3	$184K	Sell	4,780 -26	-0.5%	-$970	﹤0.01%	2440
2014 Q2	$187K	Sell	4,806 -336	-7%	-$12.5K	﹤0.01%	2562
2014 Q1	$176K	Hold	5,142	–	–	﹤0.01%	2544
2013 Q4	$108K	Sell	5,142 -337	-6%	-$8.52K	﹤0.01%	2651
2013 Q3	$129K	Sell	5,479 -74	-1%	-$2.1K	﹤0.01%	2649
2013 Q2	$149K	Buy	+5,553	New	+$161K	﹤0.01%	2552

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MYGN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Myriad Genetics (MYGN) in Q2 2024, closing a stake of 4,619 shares — an estimated $98.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MYGN in Q2 2013 and held it in 43 quarters. The position peaked at $2.08M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Myriad Genetics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,619 Myriad Genetics shares in Q2 2024, an estimated $98.5K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Myriad Genetics in Q2 2013 and held it in 43 quarters.
Metropolitan Life Insurance Company (MetLife)'s Myriad Genetics position peaked at $2.08M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.